Lytix Biopharma: Directed Share Issue Sign of Strength

Research Note

2024-12-17

10:16

Redeye comments on the successful directed share issue of NOK100m and EUR1m primary bid offering.

Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.